Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

Benzinga · 6d ago
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.